Estamos no ar no ! Saiba mais

Abeona Therapeutics

ABEO

Valor de mercado US$ 253 mi

4,43 USD

-0,22

4,73%

No fechamento Atualizado 16 de out. 16:00 EDT

1 dia

-4,73%

5 dias

-10,14%

1 mês

-17,5%

3 meses

-36,89%

6 meses

-17,66%

No acumulado do ano

-16,57%

1 ano

-19,01%

5 anos

-80,12%

10 anos

-97,39%

Sobre: Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

Funcionários: 226

Saúde Biotecnologia

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 12,9%

Neutro 83,9%

Negativo 3,2%

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright

Abeona Therapeutics NASDAQ: ABEO highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference.

Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright

Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum

Abeona Therapeutics NASDAQ: ABEO executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the Morgan Stanley Global Healthcare Conference. Management emphasized that the launch requires a longer foundation-building period than a conventional drug because of the therapy's individualized manufacturing process, limited shelf life and specialized treatment-center requirements.

Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum

Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week

Abeona Therapeutics Inc. (NASDAQ:ABEO) had a busy week that included a new treatment center activation, an FDA approval for a drug the company licensed away and multiple fresh analyst ratings.

Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona's foundational R&D and clinical development efforts -

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™